These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
7. Detection Efficacy of Hybrid Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912 [TBL] [Abstract][Full Text] [Related]
8. Changes in Management After Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320 [TBL] [Abstract][Full Text] [Related]
9. Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
12. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer. Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431 [TBL] [Abstract][Full Text] [Related]
14. PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT. Pinot F; Le Pennec R; Abgral R; Blanc-Béguin F; Hennebicq S; Schick U; Valeri A; Fournier G; Le Roux PY; Salaun PY; Robin P Clin Genitourin Cancer; 2023 Apr; 21(2):248-257. PubMed ID: 36658064 [TBL] [Abstract][Full Text] [Related]
17. [ Perry E; Talwar A; Taubman K; Ng M; Wong LM; Booth R; Sutherland TR Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2038-2046. PubMed ID: 33399941 [TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Nikitas J; Gafita A; Benz MR; Djaïleb L; Farolfi A; Hotta M; Sonni I; Alano R; Rettig M; Shen J; Armstrong W; Grogan T; Liu S; Czernin J; Calais J Sci Rep; 2024 Oct; 14(1):24411. PubMed ID: 39420060 [TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008 [TBL] [Abstract][Full Text] [Related]
20. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]